GlobeNewswire Inc.··CelldexCelldex's Barzolvolimab Shows Durable Efficacy in Retreatment Trial
Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.
CLDXbarzolvolimabcold urticaria